Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass loss

Abstract

Heterotopic ossification (HO) is the abnormal formation of bone in extraskeletal sites. However, the mechanisms linking HO pathogenesis with bone mass dysfunction remain unclear. Here, we showed that mice harboring injury-induced and BMP4-dependent HO exhibit bone mass loss similar to that presented by patients with HO. Moreover, we found that injury-induced hyperinflammatory responses at the injury site triggered HO initiation but did not result in bone mass loss at 1 day post-injury (dpi). In contrast, a suppressive immune response promoted HO propagation and bone mass loss by 7 dpi. Correcting immune dysregulation by PD1/PDL1 blockade dramatically alleviated HO propagation and bone mass loss. We further demonstrated that fetuin-A (FetA), which has been frequently detected in HO lesions but rarely observed in HO-adjacent normal bone, acts as an immunomodulator to promote PD1 expression and M2 macrophage polarization, leading to immunosuppression. Intervention with recombinant FetA inhibited hyperinflammation and prevented HO and associated bone mass loss. Collectively, our findings provide new insights into the osteoimmunological interactions that occur during HO formation and suggest that FetA is an immunosuppressor and a potential therapeutic option for the treatment of HO.

References

[1] McCarthy EF, Sundaram M. Heterotopic ossification: a review. Skelet. Radio., 2005, 34: 609-619

[2] Regard JB et al. Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification. Nat. Med., 2013, 19: 1505-1512

[3] Shore EM, Kaplan FS. Inherited human diseases of heterotopic bone formation. Nat. Rev. Rheumatol., 2010, 6: 518-527

[4] Sims NA, Vrahnas C. Regulation of cortical and trabecular bone mass by communication between osteoblasts, osteocytes and osteoclasts. Arch. Biochem. Biophys., 2014, 561: 22-28

[5] Eastell, R., Szulc, P.J.T.l.D. & endocrinology. Use of bone turnover markers in postmenopausal osteoporosis. 5, 908–923 (2017).

[6] Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat. Rev. Endocrinol., 2013, 9: 522-536

[7] Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann. Intern. Med., 1990, 112: 352-364

[8] Xing LP, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol. Rev., 2005, 208: 19-29

[9] Convente MR, Wang HT, Pignolo RJ, Kaplan FS, Shore EM. The Immunological Contribution to Heterotopic Ossification Disorders. Curr. Osteoporos. Rep., 2015, 13: 116-124

[10] Dey D et al. The traumatic bone: trauma-induced heterotopic ossification. Transl. Res., 2017, 186: 95-111

[11] Kan L, Mutso AA, McGuire TL, Apkarian AV, Kessler JA. Opioid signaling in mast cells regulates injury responses associated with heterotopic ossification. Inflamm. Res., 2014, 63: 207-215

[12] Kan LX et al. Dysregulation of Local Stem/Progenitor Cells as a Common Cellular Mechanism for Heterotopic Ossification. Stem Cells., 2009, 27: 150-156

[13] Kan C et al. Inhibition of immune checkpoints prevents injury-induced heterotopic ossification. Bone Res., 2019, 7: 33

[14] Pignolo RJ, Wang HT, Kaplan FS. Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome. Front. Endocrinol., 2020, 10: 908

[15] Kan C et al. BMP-dependent, injury-induced stem cell niche as a mechanism of heterotopic ossification. Stem cell Res. Ther., 2019, 10: 14

[16] Shehab D, Elgazzar AH, Collier BD. Heterotopic ossification. J. Nucl. Med., 2002, 43: 346-353

[17] Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat. Rev. Drug Disco., 2012, 11: 234-250

[18] Kaplan FS, Pignolo RJ, Shore EM. Granting immunity to FOP and catching heterotopic ossification in the Act. Semin Cell Dev. Biol., 2016, 49: 30-36

[19] Smith C, Kruger MJ, Smith RM, Myburgh KH. The inflammatory response to skeletal muscle injury: illuminating complexities. Sports Med., 2008, 38: 947-969

[20] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423: 337-342

[21] Hino K et al. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J. Clin. Invest., 2017, 127: 3339-3352

[22] Agarwal, S. et al. Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification. 113, E338–E347 (2016).

[23] Chen Y et al. Targeted pathological collagen delivery of sustained-release rapamycin to prevent heterotopic ossification. Sci. Adv., 2020, 6: eaay9526

[24] Qureshi AT et al. Inhibition of Mammalian Target of Rapamycin Signaling with Rapamycin Prevents Trauma-Induced Heterotopic Ossification. Am. J. Pathol., 2017, 187: 2536-2545

[25] Warnatsch A et al. Reactive Oxygen Species Localization Programs Inflammation to Clear Microbes of Different Size. Immunity, 2017, 46: 421-432

[26] Ostergaard M et al. ROS dependence of cyclooxygenase-2 induction in rats subjected to unilateral ureteral obstruction. Am. J. Physiol. Ren. Physiol., 2014, 306: F259-F270

[27] Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat. Rev. Clin. Oncol., 2019, 16: 356-371

[28] Kodumudi KN et al. A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers. Clin. Cancer Res., 2010, 16: 4583-4594

[29] Liu X, Hoft DF, Peng GY. Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy. J. Clin. Investig., 2020, 130: 1073-1083

[30] Lees-Shepard JB et al. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. Elife, 2018, 7: e40814

[31] Kan C et al. Gli1-labeled adult mesenchymal stem/progenitor cells and hedgehog signaling contribute to endochondral heterotopic ossification. Bone, 2018, 109: 71-79

[32] LaFleur MW et al. PTPN2 regulates the generation of exhausted CD8(+) T cell subpopulations and restrains tumor immunity. Nat. Immunol., 2019, 20: 1335

[33] Hatsell SJ et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci. Transl. Med., 2015, 7: 303ra137

[34] Dey D et al. Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. Sci. Transl. Med., 2016, 8: 366ra163

[35] Hwang C et al. Activin A does not drive post-traumatic heterotopic ossification. Bone, 2020, 138: 115473

[36] Pal D et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med., 2012, 18: 1279

[37] Jahnen-Dechent W, Heiss A, Schafer C, Ketteler M. Fetuin-A Regulation of Calcified Matrix Metabolism. Circ. Res., 2011, 108: 1494-1509

[38] Yang YJ et al. AHSG gene polymorphisms are associated with bone mineral density in Caucasian nuclear families. Eur. J. Epidemiol., 2007, 22: 527-532

[39] Mukhopadhyay S, Bhattacharya S. Plasma fetuin-A triggers inflammatory changes in macrophages and adipocytes by acting as an adaptor protein between NEFA and TLR-4. Diabetologia, 2016, 59: 859-860

[40] Tanaka S et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest., 1993, 91: 257-263

[41] Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur. J. Clin. Invest., 2011, 41: 1361-1366

[42] Jaworski Z, Duck B, Sekaly GJJOA. Kinetics of osteoclasts and their nuclei in evolving secondary Haversian systems. J. Anat., 1981, 133: 397-405

[43] Kan L et al. Substance P signaling mediates BMP-dependent heterotopic ossification. J. Cell Biochem., 2011, 112: 2759-2772

[44] Sorkin M et al. Regulation of heterotopic ossification by monocytes in a mouse model of aberrant wound healing. Nat. Commun., 2020, 11: 722

[45] Gray AB, Telford RD, Collins M, Weidemann MJ. The response of leukocyte subsets and plasma hormones to interval exercise. Med. Sci. Sports Exerc., 1993, 25: 1252-1258

[46] Czigner A et al. Kinetics of the cellular immune response following closed head injury. Acta Neurochir. (Wien.), 2007, 149: 281-289

[47] Riley LK, Rupert J. Evaluation of Patients with Leukocytosis. Am. Fam. Phys., 2015, 92: 1004-1011

[48] Dubinski D et al. Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma. J. Neurooncol., 2018, 137: 503-510

[49] Chatterjee P et al. Adipocyte Fetuin-A contributes to macrophage migration into adipose tissue and polarization of macrophages. J. Biol. Chem., 2013, 288: 28324-28330

[50] Huang, B. et al. Osteoblasts secrete Cxcl9 to regulate angiogenesis in bone. Nat. Commun. 7, 13885 (2016).

[51] Hatzistergos KE et al. Stimulatory effects of mesenchymal stem cells on cKit+ cardiac stem cells are mediated by SDF1/CXCR4 and SCF/cKit signaling pathways. Circ. Res., 2016, 119: 921-930

[52] Wang H, Sama AE. Anti-inflammatory role of Fetuin-A in injury and infection. Curr. Mol. Med., 2012, 12: 625-633

[53] Andersson U et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med., 2000, 192: 565-570

[54] Convente MR et al. Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1(R206H) mouse model of fibrodysplasia ossificans progressiva. J. Bone Min. Res., 2018, 33: 269-282

[55] Torossian F et al. Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. JCI Insight, 2017, 2: e96034

[56] Olmsted-Davis E, Mejia J, Salisbury E, Gugala Z, Davis AR. A population of M2 macrophages associated with bone formation. Front. Immunol., 2021, 12: 686769

[57] Barruet E et al. NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight, 2018, 3: e122958

[58] Huang Y et al. Macrophages in heterotopic ossification: from mechanisms to therapy. NPJ Regen. Med., 2021, 6: 70

[59] Ruffell D et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc. Natl. Acad. Sci., 2009, 106: 17475-17480

[60] Seto J et al. Accelerated growth plate mineralization and foreshortened proximal limb bones in Fetuin-A knockout mice. PLoS One., 2012, 7: e47338

[61] Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem, 1996, 271: 12755-12761

[62] Binkert C et al. Regulation of osteogenesis by fetuin. J Biol Chem, 1999, 274: 28514-28520

[63] Szweras M et al. alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem, 2002, 277: 19991-19997

[64] Schure R et al. Impact of matrix metalloproteinases on inhibition of mineralization by fetuin. J Periodontal Res, 2013, 48: 357-366

Funding

National Natural Science Foundation of China (National Science Foundation of China)(32070916)

Natural Science Foundation of Anhui Province (Anhui Provincial Natural Science Foundation)(1508085MC45)

National Key Research and Development Program of China (reference number 2019YFA0801801)